Anderson J
Royal Hallamshire Hospital, Sheffield.
Hosp Med. 2000 Sep;61(9):660-3. doi: 10.12968/hosp.2000.61.9.1426.
In men with locally advanced prostate cancer, bicalutamide 150 mg monotherapy provides a similar disease outcome to medical or surgical castration. However, castration is associated with loss of sexual interest and function, decreased energy and an increased risk of osteoporotic fractures. Bicalutamide 150 mg monotherapy has less impact on sexual interest and physical capacity than castration.
对于局部晚期前列腺癌男性患者，比卡鲁胺150mg单药治疗可提供与药物或手术去势相似的疾病转归。然而，去势会导致性兴趣和性功能丧失、精力下降以及骨质疏松性骨折风险增加。与去势相比，比卡鲁胺150mg单药治疗对性兴趣和身体能力的影响较小。
